Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 immunogenicity and safety study of VLA15 Lyme disease vaccine in healthy adults
2018-003379-37Phase 2Completed
- Sponsor
- Valneva
- Start
- Mar 2019
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of Lyme Disease Vaccine Recombinant OspA in Lyme borreliosis (2 arms), sponsored by Valneva. Primary endpoint: Primary immunogenicity endpoints. Started Mar 2019; status: completed.
02
Drugs
Lyme Disease Vaccine Recombinant OspA
03
Conditions
Lyme borreliosis
Beyond the preview
Go deeper on 2018-003379-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003379-37.